iratumumab

in phase I/II clinical trials for treatment of CD30+ lymphomas

Also Known As:

5F11 monoclonal antibody; MDX-060 monoclonal antibody; MDX060 monoclonal antibody

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        iratumumab: 3
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        iratumumab: 3
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        iratumumab: 3

Experts

1.	Groll, Andreas H: 1 article (03/2021)
2.	Kyriakidis, Ioannis: 1 article (03/2021)
3.	Roilides, Emmanuel: 1 article (03/2021)
4.	Rossig, Claudia: 1 article (03/2021)
5.	Tragiannidis, Athanasios: 1 article (03/2021)
6.	Vasileiou, Eleni: 1 article (03/2021)
7.	Camodeca, Caterina: 1 article (01/2018)
8.	D'Arrigo, Cristina: 1 article (01/2018)
9.	Ferrari, Nicoletta: 1 article (01/2018)
10.	Galante, Denise: 1 article (01/2018)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "In particular, both inhibitors reduce CD30 shedding maintaining the anti-tumor effects of the ADC Brentuximab-Vedotin or the anti-CD30 Iratumumab on HL cells. "
2.	Lymphoma (Lymphomas) 01/01/2007 - "Further clinical evaluation of antibodies has been based largely on our knowledge of antigen expression on the surface of lymphoma cells and has led to the development of antibodies against CD22 (unconjugated epratuzumab and calicheamicin conjugated CMC-544 [inotuzumab ozogamicin]), CD80 (galiximab), CD52 (alemtuzumab), CD2 (MEDI-507 [siplizumab]), CD30 (SGN-30 and MDX-060 [iratumumab]), and CD40 (SGN-40). "
3.	Bites and Stings (Sting) 03/05/2021 - "A detailed literature review until January 2021 was conducted regarding pediatric patient populations treated with agents that target CD2 (alefacept), CD3 (bispecific T-cell engager [BiTE] blinatumomab), CD19 (denintuzumab mafodotin, B43, BiTEs blinatumomab and DT2219ARL, the immunotoxin combotox, and chimeric antigen receptor [CAR] T-cell therapies tisagenlecleucel and axicabtagene ciloleucel), CD20 (rituximab and biosimilars, 90Y-ibritumomab tiuxetan, ofatumumab, and obinutuzumab), CD22 (epratuzumab, inotuzumab ozogamicin, moxetumomab pasudotox, BiTE DT2219ARL, and the immunotoxin combotox), CD25 (basiliximab and inolimomab), CD30 (brentuximab vedotin and iratumumab), CD33 (gemtuzumab ozogamicin), CD38 (daratumumab and isatuximab), CD52 (alemtuzumab), CD66b (90Y-labelled BW 250/183), CD248 (ontuxizumab) and immune checkpoint inhibitors against CTLA-4 (CD152; abatacept, ipilimumab and tremelimumab) or with PD-1/PD-L1 blockade (CD279/CD274; atezolizumab, avelumab, camrelizumab, durvalumab, nivolumab and pembrolizumab). "

Related Drugs and Biologics

1.	Inotuzumab Ozogamicin
2.	Brentuximab Vedotin
3.	Alemtuzumab (Campath)
4.	epratuzumab
5.	Biosimilar Pharmaceuticals
6.	Antigens
7.	Immunotoxins (Immunotoxin)
8.	Antibodies
9.	Immune Checkpoint Inhibitors
10.	Calicheamicins